Jumex, Chinoin Pharmaceutical and Chemical Works Private
the product in the database has an inactive status
indications:
Treatment of Parkinson's disease and symptomatic parkinsonism: monotherapy in the early stage of the disease to delay the introduction of levodopa and in combination with levodopa (with a peripheral decarboxylase inhibitor or without an inhibitor). The use of selegiline in severe cases of Parkinson's disease may reduce the severity of symptoms.
A selective and irreversible MAO-B inhibitor. It inhibits Dopamine reuptake in presynaptic dopaminergic receptors. Selegiline, by inhibiting MAO-B, increases the concentration of Dopamine, and when co-administered with levodopa, it increases dopaminergic activity in the striatum. After oral administration, the drug is well absorbed from the gastrointestinal tract and is rapidly metabolised. The main metabolites are: methamphetamine (T05 20.5 h), amphetamine (T0,517.7 h) and N-demethylserlegiline (T.0,5 - 2 h). It is mainly excreted in the urine.
Contraindications:
Hypersensitivity to selegiline or other components of the preparation. Concomitant use of selective serotonin reuptake inhibitors (SSRIs), serotonin and noradrenaline reuptake inhibitors (venlafaxine), sympathomimetics, tricyclic antidepressants, MAO inhibitors (eg linzolid), opioids (pethidine). Active peptic ulcer of the stomach or duodenum. When using the drug with levodopa, contraindications to the use of levodopa should be considered.
Precautions:
Use with caution in patients with unstable hypertension, cardiac arrhythmias, severe angina, severe liver or kidney problems, psychosis, or peptic ulcers. Caution should be exercised in patients treated with MAO inhibitors and treated under general anesthesia. There is an increased risk of hypotensive response when co-administered with levodopa and in patients with risk factors for cardiovascular disease. The addition of selegiline to the administered levodopa may not be beneficial to patients who exhibit a variable, dose-independent response to treatment. Exercise caution when using selegiline with other medicines and o.u.n substances - avoid drinking alcohol at the same time. The preparation contains lactose and should not be used in patients with rare hereditary galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption.
Pregnancy and lactation:
Do not use during pregnancy and breast-feeding.
Side effects:
The drug used as monotherapy is generally well tolerated. Monotherapy can often occur: headache and dizziness, nausea, bradycardia, slight increase in liver enzymes. Uncommon: mild transient sleep disorders, dry mouth, tachycardia, mood changes. Rare: skin reactions, orthostatic hypotension. Frequency unknown: urinary retention, increased sexual activity. In combination with levodopa, side effects associated with its administration may increase (restlessness, hyperkinesia, involuntary movements, agitation, confusion, hallucinations, orthostatic hypotension, arrhythmia) - in the case of combination therapy with selegiline, the dose of levodopa can be reduced by approx. . thirty%.
Dosage:
Orally. Adults, either alone or in combination with levodopa: 5-10 mg in one daily dose or two divided doses given in the morning and early afternoon. During the concomitant use of selegiline and levodopa, the dose of levodopa may be reduced (on average by 30%). Do not use a dose of more than 10 mg a day. There are no data on dose adjustments in patients with moderate hepatic or renal impairment.
(C)
